Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. (Q35797022)

10 August 2017

title

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. (English)

1 reference

10 August 2017

1 reference

1 reference

1 reference

0 references

John M Lachin

2

0 references

Steven E. Kahn

object named as

Steven E Kahn

1

0 references

Bernard Zinman

3

object named as

Bernard Zinman

1 reference

10 August 2017

4

Steven M Haffner

1 reference

10 August 2017

8

William H Herman

1 reference

10 August 2017

R Paul Aftring

5

1 reference

10 August 2017

Gitanjali Paul

6

1 reference

10 August 2017

Barbara G Kravitz

7

1 reference

10 August 2017

Giancarlo Viberti

9

1 reference

10 August 2017

Rury R Holman

10

1 reference

10 August 2017

ADOPT Study Group

11

1 reference

10 August 2017

language of work or name

English

0 references

publication date

17 March 2011

1 reference

10 August 2017

1 reference

10 August 2017

volume

60

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

1552-1560

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

10 August 2017

copyright license

start time

30 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Use and abuse of HOMA modeling

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Estimation and comparison of changes in the presence of informative right censoring: conditional linear model

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Paradoxical Inhibition of Insulin Secretion by Glucose in Human Diabetes Mellitus*

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Lipotoxicity in human pancreatic islets and the protective effect of metformin

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3292330

25 September 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/21415383

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21415383

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2337/DB10-1392

1 reference

10 August 2017

1 reference

10 August 2017

1 reference